FDA advisers vote against combination therapies of GSK's blood cancer drug – Reuters

Written by

admin

in

  1. FDA advisers vote against combination therapies of GSK’s blood cancer drug  Reuters
  2. FDA questions safety of GSK’s multiple myeloma drug  STAT
  3. Sell Rating on GlaxoSmithKline Due to Concerns Over Blenrep’s Ocular Toxicity and Limited US Trial Applicability  TipRanks
  4. GSK’s Blenrep US comeback hindered by eye safety concerns  Yahoo Finance
  5. Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel  MedPage Today

Continue Reading

More posts